BioSpace News Archive

Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced that it has signed an agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has completed its Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) and is preparing to initiate the Phase 2 LUNA trial of ADVM-022, a single intravitreal (IVT) injection for wet age-related macular degeneration (wet AMD).

Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced that the Company has further adjourned its annual general and special meeting of shareholders.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the William Blair Biotech Focus Conference 2022.

CytomX Therapeutics, Inc. announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive /human epidermal growth factor receptor 2 -non-amplified breast cancer met its primary efficacy endpoint of confirmed objective response rate of greater than 10 percent by central radiology review.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company’s Phase 2/3 ReMEDy2 trial studying the use of the Company’s product candidate, DM199, to treat acute ischemic stroke (AIS) patients.

Immunome, Inc. today announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing.

Pharvaris today announced that it will host a virtual webinar, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options on Wednesday, July 13, 2022, at 10:00 a.m. ET/16:00 CET.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the opening of its new Twist Boston location in Quincy, Massachusetts.

Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team.